The results summarized in the abstract are under embargo according to ASCO rules and regulations until the abstract is published online on
Acceptance and presentation of this data represents an important milestone for Telo, as the results summarize the completion of two important stages in Telo's collaboration with the
Telo's lead product is designed to identify high-risk SMM patients who are likely to benefit from earlier treatment intervention. Of greater importance, the test also identifies the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. These patients can be regularly monitored using Telo's test - In fact, stable SMM patients may be tested up to every three months on an ongoing basis. There are over 200,000 SMM patients in the
We are thrilled about the acceptance of our SMM abstract for presentation and publication at ASCO 2023,' said
About ASCO
About Multiple Myeloma
Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ('MGUS') and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as
About TELO
Contact:
Tel: 678-429-5582
Email: kris.weinberg@telodx.com
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute 'forward-looking information' under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as 'intends', 'will', or variations of such words and phrases or statements that certain actions, events or results 'will' occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
(C) 2023 Electronic News Publishing, source